Pharmaceutical Executive-04-26-2006

Pharmaceutical Executive

A new study details the physiological reasons why COX-2 inhibitorsincrease the risk of heart disease. Suppressing the production of one key fact does reduce pain, but it also deprives the body of a mechanism to curb blood clots, resist artery hardening, and regulate blood pressure.

Pharmaceutical Executive

April 26, 2006

During the past two weeks, companies from a half dozen states and three foreign lands joined forces. Here?s an update on who?s working with whom.